Switching From Protease Inhibitor (PI) to Etravirine in HIV-1 Infected Subjects With Viremia Suppression
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is a 48 week randomized, prospective, controlled, open-label, proof-of-concept pilot
clinical trial.
Patients with HIV-1 infection on HAART PI-based regimen will be randomized to switch from the
PI to etravirine (400 mg dissolved in water every 24 hours) or to continue with the same
approach.
The aim of the study is to compare the virological efficacy of the etravirine-based regimen
with standard PI-containing regimen.
Phase:
Phase 3
Details
Lead Sponsor:
Germans Trias i Pujol Hospital
Treatments:
Anti-Retroviral Agents Etravirine HIV Protease Inhibitors Protease Inhibitors